Collegium Pharmaceutical (COLL) Total Non-Current Liabilities (2018 - 2025)

Collegium Pharmaceutical's Total Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $1.4 billion for Q4 2025.

• On a quarterly basis, Total Non-Current Liabilities fell 5.47% year-over-year to $1.4 billion in Q4 2025; TTM through Dec 2025 was $1.4 billion, a 5.47% decrease from a year earlier, with the FY2025 full-year figure at $1.4 billion, down 5.47% from the prior year.
• Total Non-Current Liabilities improved to $1.4 billion in Q4 2025 per COLL's latest filing, from $1.3 billion in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $1.4 billion in Q4 2024 and bottomed at $947.9 million in Q4 2023.
• The 3-year median for Total Non-Current Liabilities is $1.4 billion (2025), against an average of $1.3 billion.
• Across the five-year window, Total Non-Current Liabilities surged 51.24% in 2024 and retreated 5.47% in 2025, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $947.9 million in 2023, then jumped by 51.24% to $1.4 billion in 2024, then declined by 5.47% to $1.4 billion in 2025.
• Per Business Quant, the three latest COLL Total Non-Current Liabilities figures stand at $1.4 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.4 billion (Q2 2025).